HRP20100227T1 - Stanice domaćini tumora preuređene da proizvode ligand koji inducira apoptozu povezanu s faktorom nekroze tumora (trail) - Google Patents

Stanice domaćini tumora preuređene da proizvode ligand koji inducira apoptozu povezanu s faktorom nekroze tumora (trail) Download PDF

Info

Publication number
HRP20100227T1
HRP20100227T1 HR20100227T HRP20100227T HRP20100227T1 HR P20100227 T1 HRP20100227 T1 HR P20100227T1 HR 20100227 T HR20100227 T HR 20100227T HR P20100227 T HRP20100227 T HR P20100227T HR P20100227 T1 HRP20100227 T1 HR P20100227T1
Authority
HR
Croatia
Prior art keywords
cells
tumor
necrosis factor
tumor necrosis
trail
Prior art date
Application number
HR20100227T
Other languages
English (en)
Croatian (hr)
Inventor
M. Gianni Alessandro
Carlo-Stella Carmelo
Colotta Francesco
Original Assignee
Dompe' S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe' S.P.A. filed Critical Dompe' S.P.A.
Publication of HRP20100227T1 publication Critical patent/HRP20100227T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464438—Tumor necrosis factors [TNF], CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HR20100227T 2004-07-29 2010-04-19 Stanice domaćini tumora preuređene da proizvode ligand koji inducira apoptozu povezanu s faktorom nekroze tumora (trail) HRP20100227T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017907A EP1621550A1 (en) 2004-07-29 2004-07-29 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
PCT/EP2005/007957 WO2006010558A1 (en) 2004-07-29 2005-07-21 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)

Publications (1)

Publication Number Publication Date
HRP20100227T1 true HRP20100227T1 (hr) 2010-07-31

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100227T HRP20100227T1 (hr) 2004-07-29 2010-04-19 Stanice domaćini tumora preuređene da proizvode ligand koji inducira apoptozu povezanu s faktorom nekroze tumora (trail)

Country Status (25)

Country Link
US (1) US20070264231A1 (ko)
EP (2) EP1621550A1 (ko)
JP (1) JP5042826B2 (ko)
KR (1) KR20070047757A (ko)
CN (1) CN101076540B (ko)
AT (1) ATE455847T1 (ko)
AU (1) AU2005266543B2 (ko)
BR (1) BRPI0513855A (ko)
CA (1) CA2571426A1 (ko)
DE (1) DE602005019050D1 (ko)
DK (1) DK1771468T3 (ko)
ES (1) ES2340400T3 (ko)
HK (1) HK1110874A1 (ko)
HR (1) HRP20100227T1 (ko)
IL (1) IL180233A (ko)
MX (1) MX2007001152A (ko)
NO (1) NO20070956L (ko)
NZ (1) NZ552223A (ko)
PL (1) PL1771468T3 (ko)
PT (1) PT1771468E (ko)
RS (1) RS51381B (ko)
RU (1) RU2390558C2 (ko)
SI (1) SI1771468T1 (ko)
WO (1) WO2006010558A1 (ko)
ZA (1) ZA200701231B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005264993A1 (en) * 2004-06-18 2006-01-26 Genentech, Inc. Use of Apo2L receptor agonists and NK cells or NK cell activators
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
EP2163250B1 (en) * 2007-05-18 2013-01-09 National University Corporation Asahikawa Medical University Anticancer therapy by transplanting vascular endothelial progenitor cells
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
CN105950630A (zh) * 2012-02-01 2016-09-21 浦项工科大学校产学协力团 同时表达十二聚体trail及hsv-tk自杀基因的载体及利用其的抗癌干细胞治疗剂
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
EP3209382B1 (en) 2014-10-24 2020-11-25 Calidi Biotherapeutics, Inc. Combination immunotherapy approach for treatment of cancer
EP3434762B1 (en) * 2015-07-29 2021-03-17 ONK Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
US20210230542A1 (en) * 2018-06-06 2021-07-29 Stemcell Technologies Canada Inc. Kits, compositions and methods for cell enrichment
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
KR20210142665A (ko) 2019-03-21 2021-11-25 오엔케이 테라퓨틱스 리미티드 세포 사멸에 대한 증가된 내성을 갖는 변형된 면역 효과기 세포
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1224712C (zh) * 1997-06-04 2005-10-26 牛津生物医学（英国）有限公司 载体
WO2002022175A2 (en) * 2000-09-11 2002-03-21 Musc Foundation For Research Development Method and composition for treating tumors by selective induction of apoptosis
WO2002066044A2 (en) * 2000-10-24 2002-08-29 Immunex Corporation Method for dendritic cells based immunotherapy of tumors using combination therapy
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
RU2390558C2 (ru) 2010-05-27
BRPI0513855A (pt) 2008-05-20
ES2340400T3 (es) 2010-06-02
DK1771468T3 (da) 2010-05-25
WO2006010558A1 (en) 2006-02-02
NO20070956L (no) 2007-02-20
EP1771468B1 (en) 2010-01-20
RU2007107369A (ru) 2008-09-10
RS51381B (en) 2011-02-28
CN101076540A (zh) 2007-11-21
PL1771468T3 (pl) 2010-07-30
CA2571426A1 (en) 2006-02-02
NZ552223A (en) 2009-01-31
HK1110874A1 (en) 2008-07-25
CN101076540B (zh) 2012-10-24
AU2005266543A1 (en) 2006-02-02
SI1771468T1 (sl) 2010-07-30
KR20070047757A (ko) 2007-05-07
AU2005266543B2 (en) 2012-02-02
US20070264231A1 (en) 2007-11-15
MX2007001152A (es) 2007-04-18
EP1621550A1 (en) 2006-02-01
PT1771468E (pt) 2010-04-20
JP2008507961A (ja) 2008-03-21
ZA200701231B (en) 2008-08-27
IL180233A0 (en) 2007-07-04
DE602005019050D1 (de) 2010-03-11
IL180233A (en) 2010-12-30
WO2006010558A8 (en) 2006-08-24
EP1771468A1 (en) 2007-04-11
JP5042826B2 (ja) 2012-10-03
ATE455847T1 (de) 2010-02-15

Similar Documents

Publication Publication Date Title
HRP20100227T1 (hr) Stanice domaćini tumora preuređene da proizvode ligand koji inducira apoptozu povezanu s faktorom nekroze tumora (trail)
Cao et al. Antitumor activity of polysaccharide extracted from Pleurotus ostreatus mycelia against gastric cancer in vitro and in vivo
Ahn et al. Human adipose tissue-derived mesenchymal stem cells inhibit melanoma growth in vitro and in vivo
Wang et al. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation
Kim et al. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886
Kamalabadi-Farahani et al. Anti-tumour effects of TRAIL-expressing human placental derived mesenchymal stem cells with curcumin-loaded chitosan nanoparticles in a mice model of triple negative breast cancer
JP2008507961A5 (ko)
CN108060132A (zh) 一种基于肿瘤细胞与肿瘤相关成纤维细胞的3d共培养模型
CN111888376B (zh) 一种负载顺铂的纤维蛋白胶复合体系联合治疗系统
Cheung et al. Characteristics of a low‐molecular‐weight factor extracted from mouse tumors that affects in vitro properties of macrophages
Li et al. Mesenchymal stem cells in gastric cancer: vicious but hopeful
Abd et al. Hypoxia-induced cancer cell reprogramming: a review on how cancer stem cells arise
CN103816535B (zh) 一种肿瘤疫苗及其制备方法
CN106188244B (zh) 抑制癌细胞活性的短肽治疗剂及含有它的医药组合物
CN103861107A (zh) 一种药物组合物及其用途
CN109939127A (zh) Nk细胞的应用及包括该nk细胞的药物组合物及其应用
CN106075453A (zh) 一种抗肿瘤药物制剂组合
Jain et al. Buccal metastasis in a case of carcinoma breast: A rare case report with review of literature
Kaidar-Person et al. Lymphoepithelioma‐Like Carcinoma of the Salivary Gland: Is Radiotherapy Alone Adequate?
CN101744848B (zh) Fhl3在制备用于治疗肿瘤的药物中的用途
CN101683518B (zh) Fhl1在制备用于治疗肿瘤的药物中的用途
Lyu et al. Halogen-bridged binuclear iridium (iii) complexes with enhanced photodynamic therapeutic effects in mitochondria
Wang et al. Platinum nanoparticles enhance osteogenic differentiation of human dental follicle stem cells via scavenging ROS
CN108143730A (zh) 褪黑素在霍奇金淋巴瘤治疗中的应用
Yang et al. The effects of mesenchymal stem cells on oral cancer and possible therapy regime